Global Guillain-Barre Syndrome Drugs Market Report 2024

Guillain-Barre Syndrome Drugs Global Market Report 2024 – By Drug Class (Immunoglobulins (IVIG), Corticosteroids, Plasma Exchange), By Treatment Type (First-Line Treatment, Adjunctive Or Supportive Treatment), By Application (Clinic, Hospital, Other Applications) – Market Size, Trends, And Global Forecast 2024-2033

Guillain-Barre Syndrome Drugs Global Market Report 2024

Starting Price : $5000.00 $4000.00 | Pages : 175 | Published : October 2024 | Delivery Time: 2-3 business days | Format : pdf

Need assistance or more information before the purchase?

Enquire Before Buying
Guillain-Barre Syndrome Drugs Global Market Report 2024

Proud Members Of

checkslacipN checkaoirsN checkscipN

Guillain-Barre Syndrome Drugs Market Definition

Guillain-Barre syndrome drugs refer to medications administered to manage the symptoms and complications of Guillain-Barre syndrome (GBS), an autoimmune disorder characterized by the immune system attacking the nervous system. These drugs are primarily aimed at modulating the peripheral immune system's activity to halt the progression of the disease and manage its symptoms.

The main types of Guillain-Barre syndrome drug classes include immunoglobulins (IVIG), corticosteroids, and plasma exchange. Intravenous immunoglobulin (IVIG) is a medication made from pooled human blood plasma that contains a high concentration of antibodies. They are used in first-line treatment and adjunctive or supportive treatments and find several applications in clinics, hospitals, and others.

Guillain-Barre Syndrome Drugs Market Segmentation

The guillain-barre syndrome drugs market covered in this report is segmented –

1) By Drug Class: Immunoglobulins (IVIG), Corticosteroids, Plasma Exchange

2) By Treatment Type: First-Line Treatment, Adjunctive Or Supportive Treatment

3) By Application: Clinic, Hospital, Other Applications

Global Guillain Barre Syndrome Drugs Market Size 2023 to 2028: Graph

Guillain-Barre Syndrome Drugs Market Size 2024 And Growth Rate

The Guillain-Barre syndrome drugs market size has grown strongly in recent years. It will grow from $1.08 billion in 2023 to $1.17 billion in 2024 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to progress in the field of research and development, governmental programs and assistance with regulations, increased focus on neurology and autoimmune diseases, increased focus on reducing healthcare costs, and growth in demand for hospital and clinic services.

Guillain-Barre Syndrome Drugs Market Growth Forecast

The Guillain-Barre syndrome drugs market size is expected to see strong growth in the next few years. It will grow to $1.59 billion in 2028 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period can be attributed to the growing rate of guillain-barre syndrome (GBS) incidence, increasing recognition and recognition rates, growing geriatric population, increasing role of hospital pharmacies and retail pharmacies, and growing demand for oral and parenteral medications. Major trends in the forecast period include the development of new therapies, advancements in diagnostic tools, collaboration between pharmaceutical companies and research institutions, advancements in gene therapy, and advancements in intravenous immunoglobulin therapy.

Guillain-Barre Syndrome Drugs Market Driver: Personalized Medicine Drives Guillain-Barre Syndrome Drugs Market Growth

The growing demand for personalized medicine is expected to propel the growth of the Guillain-Barre syndrome drugs market going forward. Personalized medicine refers to tailoring medical treatment to individual characteristics, such as genetics or lifestyle, to optimize effectiveness and minimize adverse effects. The growing demand for personalized medicine is driven by its potential to provide more effective treatments, advancements in genomics, increasing disease complexity, and regulatory support. Personalized medicine in Guillain-Barre syndrome (GBS) aims to tailor treatments based on individual patient profiles to improve therapeutic outcomes and reduce adverse effects. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA (Food and Drug Administration), a US-based federal agency, approved 16 novel personalized therapies for patients with rare diseases in 2023, compared to six in 2022. Thus, the increasing demand for personalized medicine is driving the growth of the Guillain-Barre syndrome drugs market.

Global Guillain-Barre Syndrome Drugs Market Major Players

Major companies operating in the guillain-barre syndrome drugs market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Biogen Inc., Chugai Pharmaceutical Co. Ltd., Grifols SA, Octapharma AG, Cadila Healthcare Limited, Argenx SE, Alnylam Pharmaceuticals Inc., Biotest AG, CSL Behring LLC, Kedrion Biopharma Inc., Cellenkos Inc., Annexon Inc., Hansa Medical AB, Akari Therapeutics Plc, Alexion Pharmaceuticals Inc., Vitality Biopharma Inc., CuraVac Inc., Regenesance BV, Cresence AS, Shire Plc

Global Guillain-Barre Syndrome Drugs Market Trend: Innovative Humanized Monoclonal Antibodies Revolutionize Guillain-Barre Syndrome Treatment

Major companies operating in the Guillain-Barre syndrome drugs market are developing innovative products, such as humanized monoclonal antibodies, to sustain their position in the market. A humanized monoclonal antibody is a type of antibody made in the laboratory by combining a human antibody with a small part of a mouse or rat monoclonal antibody. These antibodies are explored as potential therapies due to their ability to target specific components of the immune system involved in the pathological process of GBS (Guillan-Barre syndrome). For instance, in October 2023, Annexon Inc., a US-based clinical-stage biopharmaceutical company, announced that the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) had granted orphan drug designation to ANX005 for GBS treatment. ANX005, a humanized monoclonal antibody, inhibits C1q to stop complement-mediated inflammation and neuronal damage early in GBS. Annexon has achieved target enrollment in a Phase 3 trial of ANX005 in GBS, with topline data expected in the first half of 2024. ANX005 aims to reduce inflammation and nerve damage by blocking C1q activity selectively in the nervous system, allowing rapid autoimmune damage cessation and muscle strength recovery in GBS patients.

Guillain-Barre Syndrome Drugs Market Merger And Acquisition: Grifols SA Expands Plasma Supply With Strategic Acquisition Of Biotest AG

In April 2022, Grifols SA, a Spain-based pharmaceutical company, acquired Biotest AG for $1.17 billion. The acquisition of Biotest AG by Grifols is a strategic move aimed at expanding and diversifying Grifols’ plasma supply, bolstering its operations and revenues in Europe, the Middle East, and Africa. Additionally, it facilitates collaborative efforts between Grifols and Biotest to enhance the global accessibility of plasma-derived therapies. Biotest AG is a Germany-based provider of drugs for the treatment of Guillain-Barre syndrome (GBS).

Regional Outlook For The Global Guillain-Barre Syndrome Drugs Market

North America was the largest region in the Guillain-Barre syndrome drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the guillain-barre syndrome drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the guillain-barre syndrome drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The Guillain-Barre syndrome drugs market consists of sales of monoclonal antibodies, cell therapies, and recombinant enzymes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The Guillain-Barre syndrome drugs market research report is one of a series of new reports from The Business Research Company that provides Guillain-Barre syndrome drugs market statistics, including Guillain-Barre syndrome drugs industry global market size, regional shares, competitors with a Guillain-Barre syndrome drugs market share, detailed Guillain-Barre syndrome drugs market segments, market trends and opportunities, and any further data you may need to thrive in the Guillain-Barre syndrome drugs industry. This Guillain-Barre syndrome drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Guillain-Barre Syndrome Drugs Market Report Forecast and Analysis
Report AttributeDetails
Market Size Value In 2024 $1.17 billion
Revenue Forecast In 2033 $1.59 billion
Growth Rate CAGR of 8.0% from 2024 to 2033
Base Year For Estimation 2023
Actual Estimates/Historical Data 2018-2023
Forecast Period 2024 - 2028 - 2033
Market Representation Revenue in USD Billion and CAGR from 2024 to 2033
Segments Covered 1) By Drug Class: Immunoglobulins (IVIG), Corticosteroids, Plasma Exchange
2) By Treatment Type: First-Line Treatment, Adjunctive Or Supportive Treatment
3) By Application: Clinic, Hospital, Other Applications
Regional Scope Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Additional countries that can be covered in the report for an additional fee: Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Biogen Inc., Chugai Pharmaceutical Co. Ltd., Grifols SA, Octapharma AG, Cadila Healthcare Limited, Argenx SE, Alnylam Pharmaceuticals Inc., Biotest AG, CSL Behring LLC, Kedrion Biopharma Inc., Cellenkos Inc., Annexon Inc., Hansa Medical AB, Akari Therapeutics Plc, Alexion Pharmaceuticals Inc., Vitality Biopharma Inc., CuraVac Inc., Regenesance BV, Cresence AS, Shire Plc
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Guillain-Barre Syndrome Drugs Market Characteristics

    3. Guillain-Barre Syndrome Drugs Market Trends And Strategies

    4. Guillain-Barre Syndrome Drugs Market - Macro Economic Scenario

    4.1. Impact Of High Inflation On The Market

    4.2. Ukraine-Russia War Impact On The Market

    4.3. COVID-19 Impact On The Market

    5. Global Guillain-Barre Syndrome Drugs Market Size and Growth

    5.1. Global Guillain-Barre Syndrome Drugs Market Drivers and Restraints

    5.1.1. Drivers Of The Market

    5.1.2. Restraints Of The Market

    5.2. Global Guillain-Barre Syndrome Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)

    5.3. Global Guillain-Barre Syndrome Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

    6. Guillain-Barre Syndrome Drugs Market Segmentation

    6.1. Global Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Immunoglobulins (IVIG)

    Corticosteroids

    Plasma Exchange

    6.2. Global Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    First-Line Treatment

    Adjunctive Or Supportive Treatment

    6.3. Global Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Clinic

    Hospital

    Other Applications

    7. Guillain-Barre Syndrome Drugs Market Regional And Country Analysis

    7.1. Global Guillain-Barre Syndrome Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    7.2. Global Guillain-Barre Syndrome Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8. Asia-Pacific Guillain-Barre Syndrome Drugs Market

    8.1. Asia-Pacific Guillain-Barre Syndrome Drugs Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.3. Asia-Pacific Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.4. Asia-Pacific Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    9. China Guillain-Barre Syndrome Drugs Market

    9.1. China Guillain-Barre Syndrome Drugs Market Overview

    9.2. China Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.3. China Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.4. China Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    10. India Guillain-Barre Syndrome Drugs Market

    10.1. India Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.2. India Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.3. India Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11. Japan Guillain-Barre Syndrome Drugs Market

    11.1. Japan Guillain-Barre Syndrome Drugs Market Overview

    11.2. Japan Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.3. Japan Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.4. Japan Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12. Australia Guillain-Barre Syndrome Drugs Market

    12.1. Australia Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.2. Australia Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.3. Australia Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13. Indonesia Guillain-Barre Syndrome Drugs Market

    13.1. Indonesia Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.2. Indonesia Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.3. Indonesia Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14. South Korea Guillain-Barre Syndrome Drugs Market

    14.1. South Korea Guillain-Barre Syndrome Drugs Market Overview

    14.2. South Korea Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.3. South Korea Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.4. South Korea Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15. Western Europe Guillain-Barre Syndrome Drugs Market

    15.1. Western Europe Guillain-Barre Syndrome Drugs Market Overview

    15.2. Western Europe Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.3. Western Europe Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.4. Western Europe Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16. UK Guillain-Barre Syndrome Drugs Market

    16.1. UK Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.2. UK Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.3. UK Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17. Germany Guillain-Barre Syndrome Drugs Market

    17.1. Germany Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.2. Germany Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.3. Germany Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18. France Guillain-Barre Syndrome Drugs Market

    18.1. France Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.2. France Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.3. France Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19. Italy Guillain-Barre Syndrome Drugs Market

    19.1. Italy Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.2. Italy Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.3. Italy Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20. Spain Guillain-Barre Syndrome Drugs Market

    20.1. Spain Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.2. Spain Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.3. Spain Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21. Eastern Europe Guillain-Barre Syndrome Drugs Market

    21.1. Eastern Europe Guillain-Barre Syndrome Drugs Market Overview

    21.2. Eastern Europe Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.3. Eastern Europe Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.4. Eastern Europe Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22. Russia Guillain-Barre Syndrome Drugs Market

    22.1. Russia Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.2. Russia Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.3. Russia Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23. North America Guillain-Barre Syndrome Drugs Market

    23.1. North America Guillain-Barre Syndrome Drugs Market Overview

    23.2. North America Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.3. North America Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.4. North America Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24. USA Guillain-Barre Syndrome Drugs Market

    24.1. USA Guillain-Barre Syndrome Drugs Market Overview

    24.2. USA Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.3. USA Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.4. USA Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25. Canada Guillain-Barre Syndrome Drugs Market

    25.1. Canada Guillain-Barre Syndrome Drugs Market Overview

    25.2. Canada Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.3. Canada Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.4. Canada Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26. South America Guillain-Barre Syndrome Drugs Market

    26.1. South America Guillain-Barre Syndrome Drugs Market Overview

    26.2. South America Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.3. South America Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.4. South America Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27. Brazil Guillain-Barre Syndrome Drugs Market

    27.1. Brazil Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.2. Brazil Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.3. Brazil Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28. Middle East Guillain-Barre Syndrome Drugs Market

    28.1. Middle East Guillain-Barre Syndrome Drugs Market Overview

    28.2. Middle East Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.3. Middle East Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.4. Middle East Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29. Africa Guillain-Barre Syndrome Drugs Market

    29.1. Africa Guillain-Barre Syndrome Drugs Market Overview

    29.2. Africa Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.3. Africa Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.4. Africa Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    30. Guillain-Barre Syndrome Drugs Market Competitive Landscape And Company Profiles

    30.1. Guillain-Barre Syndrome Drugs Market Competitive Landscape

    30.2. Guillain-Barre Syndrome Drugs Market Company Profiles

    30.2.1. F. Hoffmann-La Roche Ltd.

    30.2.1.1. Overview

    30.2.1.2. Products and Services

    30.2.1.3. Strategy

    30.2.1.4. Financial Performance

    30.2.2. Merck & Co. Inc.

    30.2.2.1. Overview

    30.2.2.2. Products and Services

    30.2.2.3. Strategy

    30.2.2.4. Financial Performance

    30.2.3. AbbVie Inc.

    30.2.3.1. Overview

    30.2.3.2. Products and Services

    30.2.3.3. Strategy

    30.2.3.4. Financial Performance

    30.2.4. Novartis AG

    30.2.4.1. Overview

    30.2.4.2. Products and Services

    30.2.4.3. Strategy

    30.2.4.4. Financial Performance

    30.2.5. Takeda Pharmaceutical Company Limited

    30.2.5.1. Overview

    30.2.5.2. Products and Services

    30.2.5.3. Strategy

    30.2.5.4. Financial Performance

    31. Guillain-Barre Syndrome Drugs Market Other Major And Innovative Companies

    31.1. Biogen Inc.

    31.2. Chugai Pharmaceutical Co. Ltd.

    31.3. Grifols SA

    31.4. Octapharma AG

    31.5. Cadila Healthcare Limited

    31.6. Argenx SE

    31.7. Alnylam Pharmaceuticals Inc.

    31.8. Biotest AG

    31.9. CSL Behring LLC

    31.10. Kedrion Biopharma Inc.

    31.11. Cellenkos Inc.

    31.12. Annexon Inc.

    31.13. Hansa Medical AB

    31.14. Akari Therapeutics Plc

    31.15. Alexion Pharmaceuticals Inc.

    32. Global Guillain-Barre Syndrome Drugs Market Competitive Benchmarking

    33. Global Guillain-Barre Syndrome Drugs Market Competitive Dashboard

    34. Key Mergers And Acquisitions In The Guillain-Barre Syndrome Drugs Market

    35. Guillain-Barre Syndrome Drugs Market Future Outlook and Potential Analysis

    35.1 Guillain-Barre Syndrome Drugs Market In 2028 - Countries Offering Most New Opportunities

    35.2 Guillain-Barre Syndrome Drugs Market In 2028 - Segments Offering Most New Opportunities

    35.3 Guillain-Barre Syndrome Drugs Market In 2028 - Growth Strategies

    35.3.1 Market Trend Based Strategies

    35.3.2 Competitor Strategies

    36. Appendix

    36.1. Abbreviations

    36.2. Currencies

    36.3. Historic And Forecast Inflation Rates

    36.4. Research Inquiries

    36.5. The Business Research Company

    36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Table 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Table 3: Global Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 4: Global Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 5: Global Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 6: Global Guillain-Barre Syndrome Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 7: Global Guillain-Barre Syndrome Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 8: Asia-Pacific, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 9: Asia-Pacific, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 10: Asia-Pacific, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 11: China, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 12: China, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 13: China, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 14: India, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 15: India, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 16: India, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 17: Japan, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 18: Japan, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 19: Japan, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 20: Australia, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 21: Australia, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 22: Australia, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 23: Indonesia, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 24: Indonesia, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 25: Indonesia, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 26: South Korea, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 27: South Korea, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 28: South Korea, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 29: Western Europe, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 30: Western Europe, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 31: Western Europe, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 32: UK, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 33: UK, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 34: UK, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 35: Germany, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 36: Germany, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 37: Germany, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 38: France, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 39: France, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 40: France, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 41: Italy, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 42: Italy, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 43: Italy, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 44: Spain, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 45: Spain, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 46: Spain, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 47: Eastern Europe, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 48: Eastern Europe, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 49: Eastern Europe, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 50: Russia, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 51: Russia, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 52: Russia, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 53: North America, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 54: North America, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 55: North America, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 56: USA, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 57: USA, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 58: USA, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 59: Canada, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 60: Canada, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 61: Canada, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 62: South America, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 63: South America, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 64: South America, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 65: Brazil, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 66: Brazil, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 67: Brazil, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 68: Middle East, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 69: Middle East, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 70: Middle East, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 71: Africa, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 72: Africa, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 73: Africa, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 74: F. Hoffmann-La Roche Ltd. Financial Performance
  • Table 75: Merck & Co. Inc. Financial Performance
  • Table 76: AbbVie Inc. Financial Performance
  • Table 77: Novartis AG Financial Performance
  • Table 78: Takeda Pharmaceutical Company Limited Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Figure 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Figure 3: Global Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 4: Global Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 5: Global Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 6: Global Guillain-Barre Syndrome Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 7: Global Guillain-Barre Syndrome Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 8: Asia-Pacific, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 9: Asia-Pacific, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 10: Asia-Pacific, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 11: China, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 12: China, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 13: China, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 14: India, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 15: India, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 16: India, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 17: Japan, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 18: Japan, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 19: Japan, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 20: Australia, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 21: Australia, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 22: Australia, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 23: Indonesia, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 24: Indonesia, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 25: Indonesia, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 26: South Korea, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 27: South Korea, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 28: South Korea, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 29: Western Europe, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 30: Western Europe, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 31: Western Europe, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 32: UK, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 33: UK, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 34: UK, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 35: Germany, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 36: Germany, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 37: Germany, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 38: France, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 39: France, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 40: France, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 41: Italy, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 42: Italy, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 43: Italy, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 44: Spain, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 45: Spain, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 46: Spain, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 47: Eastern Europe, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 48: Eastern Europe, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 49: Eastern Europe, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 50: Russia, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 51: Russia, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 52: Russia, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 53: North America, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 54: North America, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 55: North America, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 56: USA, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 57: USA, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 58: USA, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 59: Canada, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 60: Canada, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 61: Canada, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 62: South America, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 63: South America, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 64: South America, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 65: Brazil, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 66: Brazil, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 67: Brazil, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 68: Middle East, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 69: Middle East, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 70: Middle East, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 71: Africa, Guillain-Barre Syndrome Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 72: Africa, Guillain-Barre Syndrome Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 73: Africa, Guillain-Barre Syndrome Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 74: F. Hoffmann-La Roche Ltd. Financial Performance
  • Figure 75: Merck & Co. Inc. Financial Performance
  • Figure 76: AbbVie Inc. Financial Performance
  • Figure 77: Novartis AG Financial Performance
  • Figure 78: Takeda Pharmaceutical Company Limited Financial Performance
View Report
View Report
View Report
View Report
View Report
View Report
View Report
View Report

Frequently Asked Questions

What is the definition of the guillain-barre syndrome drugs market?

Guillain-Barre syndrome drugs refer to medications administered to manage the symptoms and complications of Guillain-Barre syndrome (GBS), an autoimmune disorder characterized by the immune system attacking the nervous system. These drugs are primarily aimed at modulating the peripheral immune system's activity to halt the progression of the disease and manage its symptoms. For further insights on the guillain-barre syndrome drugs market, request a sample here

How will the guillain-barre syndrome drugs market drivers and restraints affect the guillain-barre syndrome drugs market dynamics? What forces will shape the guillain-barre syndrome drugs industry going forward?

The guillain-barre syndrome drugs market major growth driver - Personalized Medicine Drives Guillain-Barre Syndrome Drugs Market Growth. For further insights on the guillain-barre syndrome drugs market, request a sample here

What is the forecast market size or the forecast market value of the guillain-barre syndrome drugs market?

The Guillain-Barre syndrome drugs market size has grown strongly in recent years. It will grow from $1.08 billion in 2023 to $1.17 billion in 2024 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to progress in the field of research and development, governmental programs and assistance with regulations, increased focus on neurology and autoimmune diseases, increased focus on reducing healthcare costs, and growth in demand for hospital and clinic services. The Guillain-Barre syndrome drugs market size is expected to see strong growth in the next few years. It will grow to $1.59 billion in 2028 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period can be attributed to the growing rate of guillain-barre syndrome (GBS) incidence, increasing recognition and recognition rates, growing geriatric population, increasing role of hospital pharmacies and retail pharmacies, and growing demand for oral and parenteral medications. Major trends in the forecast period include the development of new therapies, advancements in diagnostic tools, collaboration between pharmaceutical companies and research institutions, advancements in gene therapy, and advancements in intravenous immunoglobulin therapy. For further insights on the guillain-barre syndrome drugs market, request a sample here

How is the guillain-barre syndrome drugs market segmented?

The guillain-barre syndrome drugs market is segmented
1) By Drug Class: Immunoglobulins (IVIG), Corticosteroids, Plasma Exchange
2) By Treatment Type: First-Line Treatment, Adjunctive Or Supportive Treatment
3) By Application: Clinic, Hospital, Other ApplicationsFor further insights on the guillain-barre syndrome drugs market,
request a sample here

Which region has the largest share of the guillain-barre syndrome drugs market? What are the other regions covered in the report?

North America was the largest region in the Guillain-Barre syndrome drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the guillain-barre syndrome drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on the guillain-barre syndrome drugs market, request a sample here.

Who are the major players in the guillain-barre syndrome drugs market?

Major companies operating in the guillain-barre syndrome drugs market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Biogen Inc., Chugai Pharmaceutical Co. Ltd., Grifols SA, Octapharma AG, Cadila Healthcare Limited, Argenx SE, Alnylam Pharmaceuticals Inc., Biotest AG, CSL Behring LLC, Kedrion Biopharma Inc., Cellenkos Inc., Annexon Inc., Hansa Medical AB, Akari Therapeutics Plc, Alexion Pharmaceuticals Inc., Vitality Biopharma Inc., CuraVac Inc., Regenesance BV, Cresence AS, Shire Plc For further insights on the guillain-barre syndrome drugs market, request a sample here.

What are the key trends in the guillain-barre syndrome drugs market?

Major trend in the guillain-barre syndrome drugs market - Innovative Humanized Monoclonal Antibodies Revolutionize Guillain-Barre Syndrome Treatment. For further insights on the guillain-barre syndrome drugs market, request a sample here.

What are the major opportunities in the guillain-barre syndrome drugs market? What are the strategies for the guillain-barre syndrome drugs market?

For detailed insights on the major opportunities and strategies in the guillain-barre syndrome drugs market, request a sample here.

How does the guillain-barre syndrome drugs market relate to the overall economy and other similar markets?

For detailed insights on guillain-barre syndrome drugs market's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the guillain-barre syndrome drugs industry?

For detailed insights on the mergers and acquisitions in the guillain-barre syndrome drugs industry, request a sample here.

What are the key dynamics influencing the guillain-barre syndrome drugs market growth? SWOT analysis of the guillain-barre syndrome drugs market.

For detailed insights on the key dynamics influencing the guillain-barre syndrome drugs market growth and SWOT analysis of the guillain-barre syndrome drugs industry, request a sample here.